United States President Donald Trump, Eli Lilly and Novo Nordisk have unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for the government’s Medicare and Medicaid programme, as well as for cash payers.
The deal, announced…
Weight-loss drug makers announce pricing agreement with Trump | Health News
